KabinsS.A., and CohenS.: Cephalothin Serum Levels in the Azotemic Patient, Antimicrobial Agents & Chemotherapy, pp. 207–214, 1965.
2.
KirbyW.M.M.: Pharmacokinetics of the Cephalosporins in Healthy Volunteers and Uremic Patients, Postgrad. Med. J.47: (Suppl.) 41–46 (Feb.) 1971.
3.
BennerE.J.: Practical Use of the Cephalosporins, Penicillins, and Aminoglycoside Antibiotics, Calif. Med.117: 17–27 (Oct.) 1972.
4.
KirbyW.M.M.: Pharmacokinetics of the Cephalosporins in Healthy Volunteers and Uremic Patients, Postgrad. Med. J.47 (Suppl.) 41–46 (Feb.) 1971.
5.
KabinsS.A., and CohenS.: Cephalothin Serum Levels in the Azotemic Patient, Antimicrobial Agents and Chemotherapy1964, pp. 207–214, 1965.
6.
MolthanL.: Positive Direct Coombs' Test Due to Cephalothin, N. Engl. J. Med.277: 123–125 (July 20) 1967.
7.
GralnickH.R.: Coombs' Positive Reactions Associated with Sodium Cephalothin Therapy, J. Amer. Med. Assoc.199: 725–726 (Mar. 6) 1967.
8.
PerkinsR.L.: Coombs' Reactivity After Cephalothin or Cephaloridine, Clin. Res.15: 426 (Oct.) 1967.
9.
McGinnisM.H.: Coombs' Positivity and Cephalothin Therapy, Transfusion6: 516 (Nov.-Dec.) 1966.
10.
PickeringM.J.: Declining Renal Function Associated with the Administration of Cephalothin, S. Med. J.63: 426–428 (Apr.) 1970.
11.
SimpsonI. J.: Nephrotoxicity and Acute Renal Failure Associated with Cephalothin and Cephaloridine, N. Z. Med. J.74: 312–315 (Nov.) 1971.
12.
BennerE.J.: Renal Damage Associated with Prolonged Administration of Ampicillin, Cephaloridine and Cephalothin. Antimicrobial Agents and Chemotherapy 1969. pp. 417–420, 1970.
13.
KayserF.H.: In Vitro Activity of Cephalosporin Antibiotics Against Gram-positive Bacteria, Postgrad. Med J.47: (Suppl.) 14–20 (Feb.) 1971.
14.
WaterworthP.M.: The Susceptibility of Pathogenic Gram-negative Bacilli to Cephalosporins, Postgrad. Med. J.47: (Suppl.) 25–31 (Feb.). 1971.
15.
TousignautD.R. (ed.): International Pharmaceutical Abstracts, 8: 587 (Abstract 8 2670) (15 Aug.) 1971, American Society of Hospital Pharmacists, Washington, D.C. 20014.
